{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:17:57Z","timestamp":1785860277772,"version":"3.56.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00279","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T04:38:36Z","timestamp":1532407116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening"],"prefix":"10.3389","volume":"8","author":[{"given":"Chi C.","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka O.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H. F.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai-Yee","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2008.9.5362","article-title":"Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials","volume":"27","author":"Sargent","year":"2009","journal-title":"J Clin Oncol."},{"key":"B3","unstructured":"National Cancer InstituteCommon Terminology Criteria for Adverse Events (CTCAE) version 4.0."},{"key":"B4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cca.2015.10.011","article-title":"Clinical whole -exome sequencing reveals a novel missense pathogenic variant of GNAO1 in a patient with infantile-onset epilepsy","volume":"451","author":"Law","year":"2015","journal-title":"Clin Chim Acta"},{"key":"B5","doi-asserted-by":"publisher","first-page":"D840","DOI":"10.1093\/nar\/gkw971","article-title":"The ExAC browser: displaying reference data information from over 60 000 exomes","volume":"45","author":"Karczewski","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther."},{"key":"B7","article-title":"Capecitabine Therapy and DPYD Genotype. Medical Genetics Summaries","author":"Dean","year":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance","volume":"5","author":"Morel","year":"2006","journal-title":"Mol Cancer Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2217\/pgs.11.72","article-title":"Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity","volume":"12","author":"Amstutz","year":"2011","journal-title":"Pharmacogenomics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","article-title":"Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time","volume":"54","author":"Lunenburg","year":"2016","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3816\/CCC.2010.n.033","article-title":"Routine dihydropyrimidine dehydrogenase testing for anticipating 5-Fluorouracil-related severe toxicities: hype or hope?","volume":"9","author":"Ciccolini","year":"2010","journal-title":"Clin Colorect Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00439-010-0879-3","article-title":"Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity","volume":"128","author":"van","year":"2010","journal-title":"Hum Genetics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"Dihydropyrimidine dehydrogenases (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapyies: update and recommendations of the French GPCO-Unicancer and RnPGX networks","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"827989","DOI":"10.1155\/2014\/827989","article-title":"Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: a meta-analysis","volume":"2014","author":"Li","year":"2014","journal-title":"Gastroenterol Res Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.2015.64.2546","article-title":"Is it finally time for a personalized medicine approach for fluorouracil-based therapies?","volume":"34","author":"Offer","year":"2016","journal-title":"J Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/clpt.2013.214","article-title":"Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era","volume":"95","author":"Gillis","year":"2014","journal-title":"Clin Pharmacol Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12253-016-0124-z","article-title":"Clinical applications of next-generation sequencing in cancer diagnosis","volume":"23","author":"Sabour","year":"2017","journal-title":"Pathol Oncol Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/j.seminoncol.2017.02.008","article-title":"Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach","volume":"44","author":"Boisdron-Celle","year":"2017","journal-title":"Semin Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/bjc.2017.289","article-title":"Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients","volume":"117","author":"Ruzzo","year":"2017","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","article-title":"DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update","volume":"28","author":"Henricks","year":"2017","journal-title":"Ann Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T04:38:48Z","timestamp":1532407128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":22,"alternative-id":["10.3389\/fonc.2018.00279"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00279","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]},"article-number":"279"}}